Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2000 Dec;84(12):1423–1425. doi: 10.1136/bjo.84.12.1423

Increase of macrophage migration inhibitory factor in sera of patients with iridocyclitis

N Kitaichi 1, S Kotake 1, Y Mizue 1, H Matsuda 1, K Onoe 1, J Nishihira 1
PMCID: PMC1723331  PMID: 11090487

Abstract

AIMS—To determine whether macrophage migration inhibitory factor (MIF) levels were increased in sera of the patients with iridocyclitis.
METHODS—Sera were obtained from 41 patients with acute iridocyclitis, 13 patients with chronic iridocyclitis, and 44 healthy control subjects. MIF levels were determined by a human MIF ELISA.
RESULTS—The average levels of MIF in the sera of patients with both acute and chronic iridocyclitis were significantly higher than that of healthy subjects.
CONCLUSION—Uveitis induces the elevation of serum MIF, which may affect various inflammatory symptoms in uveitis.



Full Text

The Full Text of this article is available as a PDF (88.3 KB).

Figure 1  .

Figure 1  

Open in a new tab

Concentration of MIF in sera of patients with acute and chronic iridocyclitis. The mean MIF concentration in the sera of patients with acute and chronic, iridocyclitis and of healthy control subjects are 28.8 (SD 3.4), 18.5 (5.9), and 4.4 (0.2) ng/ml, respectively. The average level of MIF in sera of patients with iridocyclitis is significantly higher than that of healthy control subjects (p<0.0001).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacher M., Metz C. N., Calandra T., Mayer K., Chesney J., Lohoff M., Gemsa D., Donnelly T., Bucala R. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7849–7854. doi: 10.1073/pnas.93.15.7849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beckingsale A. B., Davies J., Gibson J. M., Rosenthal A. R. Acute anterior uveitis, ankylosing spondylitis, back pain, and HLA-B27. Br J Ophthalmol. 1984 Oct;68(10):741–745. doi: 10.1136/bjo.68.10.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bernhagen J., Calandra T., Mitchell R. A., Martin S. B., Tracey K. J., Voelter W., Manogue K. R., Cerami A., Bucala R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993 Oct 21;365(6448):756–759. doi: 10.1038/365756a0. [DOI] [PubMed] [Google Scholar]
  4. Bloom B. R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966 Jul 1;153(3731):80–82. doi: 10.1126/science.153.3731.80. [DOI] [PubMed] [Google Scholar]
  5. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J. 1996 Dec;10(14):1607–1613. doi: 10.1096/fasebj.10.14.9002552. [DOI] [PubMed] [Google Scholar]
  6. Calandra T., Bernhagen J., Metz C. N., Spiegel L. A., Bacher M., Donnelly T., Cerami A., Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995 Sep 7;377(6544):68–71. doi: 10.1038/377068a0. [DOI] [PubMed] [Google Scholar]
  7. De Vos A. F., Hoekzema R., Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res. 1992 Jun;11(6):581–597. doi: 10.3109/02713689209001814. [DOI] [PubMed] [Google Scholar]
  8. Kijlstra A. The role of cytokines in ocular inflammation. Br J Ophthalmol. 1994 Dec;78(12):885–886. doi: 10.1136/bjo.78.12.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kitaichi N., Kotake S., Sasamoto Y., Namba K., Matsuda A., Ogasawara K., Onoé K., Matsuda H., Nishihira J. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci. 1999 Jan;40(1):247–250. [PubMed] [Google Scholar]
  10. Kitaichi N., Matsuda A., Kotake S., Namba K., Tagawa Y., Sasamoto Y., Ogasawara K., Iwabuchi K., Onoé K., Matsuda H. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies. Curr Eye Res. 2000 Feb;20(2):109–114. [PubMed] [Google Scholar]
  11. Kitaichi N., Ogasawara K., Iwabuchi K., Nishihira J., Namba K., Onoé K., Konishi J., Kotake S., Matsuda H., Onoé K. Different influence of macrophage migration inhibitory factor (MIF) in signal transduction pathway of various T cell subsets. Immunobiology. 2000 Jan;201(3-4):356–367. doi: 10.1016/s0171-2985(00)80090-x. [DOI] [PubMed] [Google Scholar]
  12. Matsuda A., Kotake S., Tagawa Y., Matsuda H., Nishihira J. Detection and immunolocalization of macrophage migration inhibitory factor in rat iris and ciliary epithelium. Immunol Lett. 1996 Oct;53(1):1–5. doi: 10.1016/0165-2478(96)02600-4. [DOI] [PubMed] [Google Scholar]
  13. Nishihira J., Koyama Y., Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine. 1998 Mar;10(3):199–205. doi: 10.1006/cyto.1997.0276. [DOI] [PubMed] [Google Scholar]
  14. Rothova A., Buitenhuis H. J., Meenken C., Brinkman C. J., Linssen A., Alberts C., Luyendijk L., Kijlstra A. Uveitis and systemic disease. Br J Ophthalmol. 1992 Mar;76(3):137–141. doi: 10.1136/bjo.76.3.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shimizu T., Abe R., Ohkawara A., Mizue Y., Nishihira J. Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. Biochem Biophys Res Commun. 1997 Nov 7;240(1):173–178. doi: 10.1006/bbrc.1997.7633. [DOI] [PubMed] [Google Scholar]
  16. Shimizu T., Abe R., Ohkawara A., Nishihira J. Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):659–664. doi: 10.1016/s0091-6749(99)70339-8. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES